Robert Dubois, MD

Formulary restrictions on brand name noninsulin antihyperglycemic drugs have little impact on treatment intensification patterns among low-income patients with diabetes in Medicare Part D.

The authors found no consistent pattern in the concordance between CER evidence and subsequent utilization patterns.